HIG Capital completes the acquisition of Taconic Biosciences.

HIG Capital has partnered with the management team of Taconic Biosciences to support the Company's growth as a leading global provider of research models and services to the pharmaceutical, biotechnology, CRO, and academic research industries. Financial terms were not disclosed. Taconic is a global leader in genetically engineered models and service solutions used in mission-critical life sciences research. With its strong market position and long-standing relationships, Taconic is well-positioned to benefit from the significant growth in the broader healthcare services market and more specifically in genetically engineered models growth. "HIG's investment and deep resources, particularly around M&A, will help catalyze our continued expansion and allow us to more quickly address unmet customer needs." Nancy Sandy, Taconic's new Chief Executive Officer.